Elodie Vauleon

Rennes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.

Journal: Neuro-oncology

Published: July 22, 2025

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation.

Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation.

Journal: Neuro-oncology

Published: March 24, 2025

Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study.

Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study.

Journal: Cancer

Published: November 30, 2024

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 02, 2024

Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program.

Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 22, 2024

Transformation From Atypical to Anaplastic Metastatic Meningioma: Evolutionary Turning Point Marked by Strong 18 F-FDG Avidity and Uptake Collapse From 68 GA-DOTATOC.

Transformation From Atypical to Anaplastic Metastatic Meningioma: Evolutionary Turning Point Marked by Strong 18 F-FDG Avidity and Uptake Collapse From 68 GA-DOTATOC.

Journal: Clinical nuclear medicine

Published: December 23, 2023

Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study.

Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study.

Journal: Cancers

Published: September 17, 2022

Dual IRE1 RNase functions dictate glioblastoma development.

Dual IRE1 RNase functions dictate glioblastoma development.

Journal: EMBO molecular medicine

Published: August 12, 2022

Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.

Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.

Journal: Neuro-oncology

Published: August 11, 2022

Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).

Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 04, 2022

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 28, 2022

Showing 1-12 of 47

Last Updated: 09/26/2026